BioSpace News Archive

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced the appointments of Philip T. Chase as Chief Executive Officer and Eric M. Krauland as President and Chief Scientific Officer.

Amicus Therapeutics, a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced financial results for the quarter ended March 31, 2022.

OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases.

Illuminate, Inc., the provider of software that unlocks vital unstructured clinical information lost in the EMR that can drive patient care improvements, announces the ability to identify more types of aneurysms.

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimer’s disease (AD), announces it will present “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” at the Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference.

ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing an innovative drug for the treatment of cardiovascular emergencies, announces today the presentation of positive results from the Phase 1b/2a study, ACTIMIS, in the treatment of acute ischemic stroke, at the 8th European Stroke Organisation Conference (ESOC) on Friday May 6, 2022.

Hitachi High-Tech Corporation (“Hitachi High-Tech”) has entered into a strategic partnership (the Partnership) with Invivoscribe, Inc. (“Invivoscribe”), a global provider of blood cancer testing kits and services, by undertaking a minority investment-based, third-party allotment of shares.

The Diabetes Research Institute along with the Diabetes Research Institute Foundation Canada and Alberta Diabetes Institute at the University of Alberta, Canada’s largest stand-alone research facility dedicated to finding a cure of diabetes, announced the launch of a research partnership to advance efforts to find a cure for diabetes.

Longeveron Inc. announced the resignation of Chief Executive Officer Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities.

Arcellx, Inc. (NASDAQ: ACLX), today announced the publication of clinical data from its dose escalation cohorts in its ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM).